Table 1.
Baseline characteristics of 57 patients with RA-ILD treated with abatacept.
| Variable | Sample = 57 |
|---|---|
| Epidemiologic characteristics | |
| Female sex, n (%) | 32 (56.1) |
| Caucasian race, n (%) | 56 (98.2) |
| Age in years, mean (SD) | 67.7 (22.0) |
| Clinical and laboratory characteristics | |
| Smoking status | |
| Nonsmoker, n (%) | 39 (68.4) |
| Smoker, n (%) | 9 (15.8) |
| Ex-smoker, n (%) | 9 (15.8) |
| Body mass index, mean (SD) | 27.9 (5.1) |
| Time since diagnosis of RA, months, median (IQR) | 120.6 (66.0–220.9) |
| Diagnostic delay, months, median (IQR) | 6.3 (3.7–16.0) |
| Time since diagnosis of ILD, months, median (IQR) | 48.0 (25.8–93.9) |
| Positive rheumatoid factor (>10 U/mL), n (%) | 54 (94.7) |
| Positive antipeptide citrullinated antibody (>20 U/mL), n (%) | 48 (84.2) |
| Erosive disease, n (%) | 36 (63.2) |
| Inflammatory activity | |
| 28-joint Disease Activity Score, mean (SD) | 3.8 (1.5) |
| Health Assessment Questionnaire, median (IQR) | 1.1 (0.5–1.5) |
| C-reactive protein (mg/dl), median (IQR) | 7.0 (2.5–20.7) |
| Erythrocyte sedimentation rate (mm/h), median (IQR) | 33.0 (15.0–47.0) |
| Conventional synthetic DMARDs | 47 (82.5) |
| Methotrexate, n (%) | 22 (38.5) |
| Leflunomide, n (%) | 17 (29.8) |
| Sulfasalazine, n (%) | 2 (3.6) |
| Hydroxychloroquine, n (%) | 6 (10.6) |
| Immunosuppressant | 5 (8.8) |
| Mycophenolate, n (%) | 3 (5.3) |
| Azathioprine, n (%) | 2 (3.5) |
| Antifibrotic agents, nintedanib n (%) | 1 (1.8) |
| Baseline corticosteroids, n (%) | 39 (68.4) |
| Baseline dose of corticosteroids (grams), median (IQR) | 5.0 (2.5–5.0) |
Abbreviations: RA: rheumatoid arthritis; ILD: interstitial lung disease; DMARD: disease-modifying antirheumatic drug; SD: standard deviation; IQR: interquartile range.